We are interested in Projects in all therapeutic areas and modality which possess a strong innovation potential and a team willing to take part in an entrepreneurial initiative. From monoclonal antibodies to gene therapy solutions, we welcome your proposals. The development stage needs to be between the Target ID and the lead optimisation phase within the drug discovery process.
Since the objective of EXTEND is to create new companies from academic research, we prefer Projects that are not yet incorporated into a company. Nevertheless, we will evaluate formed start-ups’ proposals as well.
It is crucial that all teams interact with their relative TTO before presenting their idea to EXTEND as to identify relevant IP rights and correctly follow the application process.
For more information, please refer to the section Apply